BR112016007237A2 - método para a profilaxia ou tratamento do lúpus eritematoso sistêmico e/ou nefrite lúpica - Google Patents
método para a profilaxia ou tratamento do lúpus eritematoso sistêmico e/ou nefrite lúpicaInfo
- Publication number
- BR112016007237A2 BR112016007237A2 BR112016007237A BR112016007237A BR112016007237A2 BR 112016007237 A2 BR112016007237 A2 BR 112016007237A2 BR 112016007237 A BR112016007237 A BR 112016007237A BR 112016007237 A BR112016007237 A BR 112016007237A BR 112016007237 A2 BR112016007237 A2 BR 112016007237A2
- Authority
- BR
- Brazil
- Prior art keywords
- prophylaxis
- treatment
- lupus erythematosus
- systemic lupus
- nephritis
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000005777 Lupus Nephritis Diseases 0.000 title abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 2
- -1 citric acid ester Chemical class 0.000 abstract 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886403P | 2013-10-03 | 2013-10-03 | |
| PCT/US2014/058738 WO2015051067A1 (en) | 2013-10-03 | 2014-10-02 | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016007237A2 true BR112016007237A2 (pt) | 2017-09-12 |
Family
ID=51842818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016007237A BR112016007237A2 (pt) | 2013-10-03 | 2014-10-02 | método para a profilaxia ou tratamento do lúpus eritematoso sistêmico e/ou nefrite lúpica |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160250238A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3052105A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016531886A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160058886A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105705149A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016007237A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2925935A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201690686A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016003979A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015051067A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020000092A1 (en) * | 2018-06-27 | 2020-01-02 | Algernon Pharmaceuticals Inc. | The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease |
| CN115515578A (zh) * | 2020-05-07 | 2022-12-23 | 诺罗瑞韦有限公司 | 用于治疗抑郁症的环丝氨酸和己酮可可碱联合疗法 |
| CN121041156A (zh) * | 2025-08-27 | 2025-12-02 | 复皙药业(上海)有限公司 | 含有替普瑞酮的具有祛红功效的膏霜及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CA2435146C (en) | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| KR20140042933A (ko) * | 2007-08-06 | 2014-04-07 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 프로테아좀 억제제 |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| SI2318419T2 (sl) * | 2008-06-17 | 2025-10-30 | Takeda Pharmaceutical Company Limited | Spojine boronat estra in njihovi farmacevtski sestavki |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| TW201309303A (zh) * | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
| WO2012177835A1 (en) * | 2011-06-22 | 2012-12-27 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
-
2014
- 2014-10-02 US US15/026,417 patent/US20160250238A1/en not_active Abandoned
- 2014-10-02 EA EA201690686A patent/EA201690686A1/ru unknown
- 2014-10-02 MX MX2016003979A patent/MX2016003979A/es unknown
- 2014-10-02 KR KR1020167010114A patent/KR20160058886A/ko not_active Withdrawn
- 2014-10-02 WO PCT/US2014/058738 patent/WO2015051067A1/en not_active Ceased
- 2014-10-02 CA CA2925935A patent/CA2925935A1/en not_active Abandoned
- 2014-10-02 CN CN201480060987.4A patent/CN105705149A/zh active Pending
- 2014-10-02 JP JP2016519782A patent/JP2016531886A/ja active Pending
- 2014-10-02 BR BR112016007237A patent/BR112016007237A2/pt not_active IP Right Cessation
- 2014-10-02 EP EP14790872.7A patent/EP3052105A1/en not_active Withdrawn
-
2017
- 2017-12-12 US US15/838,595 patent/US20180099000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2925935A1 (en) | 2015-04-09 |
| MX2016003979A (es) | 2016-06-15 |
| US20180099000A1 (en) | 2018-04-12 |
| WO2015051067A1 (en) | 2015-04-09 |
| JP2016531886A (ja) | 2016-10-13 |
| EP3052105A1 (en) | 2016-08-10 |
| KR20160058886A (ko) | 2016-05-25 |
| EA201690686A1 (ru) | 2016-08-31 |
| CN105705149A (zh) | 2016-06-22 |
| US20160250238A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015020302A2 (pt) | derivado de pirazol | |
| JOP20200011B1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| MX2017005236A (es) | Profarmacos de carbidopa y l-dopa y metodos de uso. | |
| BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
| BR112015016930A2 (pt) | formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| MX384403B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| BR112018000749A2 (pt) | métodos e composições para a diagnose e para o tratamento de adrenoleucodistrofia | |
| BR112015030399B8 (pt) | Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3 | |
| BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| MX384429B (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| BR112017028468A2 (pt) | formulação sólida oral, e método para preparar uma formulação sólida oral | |
| UA115811C2 (uk) | Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| MX381776B (es) | Formulacion acuosa que comprende paracetamol e ibuprofeno. | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| CR20150637A (es) | Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral | |
| CL2016001098A1 (es) | Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales | |
| BR112016004118A2 (pt) | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |